EUVIMEDEUVIMED entdecken
Open Access

Mutation in the Unrearranged PML Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia

Pei-Han Yu, Chen-Ying Zhu, Yuan-Yuan Kang, Hua Naranmandura iD, Chang Yang

Research · 2025-01 · 8

DOI: 10.34133/research.0696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research, online erschienen am 06.05.2025. Verfasst von Pei-Han Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology of First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Key Technologies Research and Development Program, State Administration of Traditional Chinese Medicine of the People's Republic of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Arsenic trioxide (ATO) is able to selectively target and degrade the disease-causing PML::RARα (P/R) oncoprotein in acute promyelocytic leukemia (APL) for curing the disease. However, some relapsed patients develop resistance to ATO due to mutations in the promyelocytic leukemia (PML) part of the PML::RARα fusion gene. A relapsed APL patient had shown resistance to ATO and chemotherapy and was identified to harbor a point mutation (A216V) in the unrearranged PML allele rather than the PML::RARα fusion gene. Here, we report that mutations in the unrearranged PML allele impede the ATO-induced destabilization and degradation of the wild-type P/R oncoprotein. Deletion of the coiled-coil domain in a PML mutant completely reversed wild-type P/R protein resistance to ATO by abolishing the interaction between PML and P/R proteins. Collectively, our findings reveal that a point mutation in the unrearranged PML allele can confer ATO resistance through a protein–protein interaction. Therefore, the unrearranged PML allele should also be screened for drug-resistant mutations in relapsed APL patients.

Autor:innen und Institutionen

  • Department of Hematology of First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Department of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Department of Pharmacology, Zhejiang University, Hangzhou 310058, China.
  • Cancer Center, Zhejiang University, Hangzhou 310058, China.

ORCID-Profile: Hua Naranmandura

Förderung

  • National Natural Science Foundation of China
  • Key Technologies Research and Development Program
  • State Administration of Traditional Chinese Medicine of the People's Republic of China

Zitieren

APA

Yu, P. H., Zhu, C. Y., Kang, Y. Y., Naranmandura, H., & Yang, C. (2025). Mutation in the Unrearranged PML Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia. Research, 8. https://doi.org/10.34133/research.0696

Vancouver

Yu PH, Zhu CY, Kang YY, Naranmandura H, Yang C. Mutation in the Unrearranged PML Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia. Research. 2025;8. doi:10.34133/research.0696

BibTeX
@article{Yu2025,
  author = {Yu, Pei-Han and Zhu, Chen-Ying and Kang, Yuan-Yuan and Naranmandura, Hua and Yang, Chang},
  title = {Mutation in the Unrearranged PML Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia},
  journal = {Research},
  year = {2025},
  volume = {8},
  doi = {10.34133/research.0696}
}
Kostenlos starten →